BEGIN:VCALENDAR VERSION:2.0 PRODID:-//jEvents 2.0 for Joomla//EN CALSCALE:GREGORIAN METHOD:PUBLISH BEGIN:VEVENT UID:95f2c431e46a43a82e2ba1bc16157547 CATEGORIES:Colloquium CREATED:20221130T151351 SUMMARY:Professor Hsian-Rong Tseng, UCLA LOCATION:CCB Auditorium (Room 1303) DESCRIPTION:
Liquid Biopsy Technologies for Cancer and Prenatal Diagnostics: T he Impact of Nanotechnology
The current gold standard for cancer diagnosis relies on pathologists ana lyzing tumor tissues obtained via invasive procedures like surgical ex cision or needle biopsy. However, researchers have proposed using a "l iquid biopsy" as a less invasive alternative to solid tumor biopsy.&nb sp;This approach involves analyzing blood components such as circulating tu mor cells (CTCs) and tumor-derived extracellular vesicles (EVs) that c ontain molecular contents similar to those found in the parental tumor tissues. By performing molecular analysis on CTCs and tumor-deri ved EVs, we can gain insights into the underlying biology of cancer, i dentify appropriate treatment strategies, and monitor disease progress ion. At the UCLA Liquid Biopsy Laboratory, we have developed plat form technologies including "NanoVelcro Chips" and "Click Chips" that utilize immuno-affinity agent-coated nanostructured substrates to puri fy and characterize CTCs and tumor-derived EVs. These technologie s have undergone clinical validation for cancer diagnosis, and we beli eve they could also be useful for reducing the need for invasive sampl ing of placenta tissues in prenatal diagnosis. In this presentation, I will provide an overview of our latest liquid biopsy technologie s and their clinical validation for cancer and prenatal diagnoses.
Ho sted by Professor KiBum Li
~Coffee/tea will be served prior to the lecture~
X-ALT-DESC;FMTTYPE=text/html:Liquid Biopsy Technologies for Cancer an d Prenatal Diagnostics: The Impact of Nanotechnology
The current gold standard for cancer diagnosis relies on pathologists analyzing tumor tissues obtained via invasive procedu res like surgical excision or needle biopsy. However, researchers have proposed using a "liquid biopsy" as a less invasive alternative to solid tumor biopsy. This approach involves analyzing blood componen ts such as circulating tumor cells (CTCs) and tumor-derived extracellu lar vesicles (EVs) that contain molecular contents similar to those fo und in the parental tumor tissues. By performing molecular analys is on CTCs and tumor-derived EVs, we can gain insights into the underl ying biology of cancer, identify appropriate treatment strategies, and monitor disease progression. At the UCLA Liquid Biopsy Laborator y, we have developed platform technologies including "NanoVelcro Chips " and "Click Chips" that utilize immuno-affinity agent-coated nanostru ctured substrates to purify and characterize CTCs and tumor-derived EV s. These technologies have undergone clinical validation for canc er diagnosis, and we believe they could also be useful for reducing the&nbs p;need for invasive sampling of placenta tissues in prenatal diagnosis. In this presentation, I will provide an overview of our latest liqui d biopsy technologies and their clinical validation for cancer and pre natal diagnoses.
Hosted by Professor KiBum Li
~Coffee/tea will be served prior to the lecture~
DTSTAMP:20240328T144036 DTSTART:20230404T150000 DTEND:20230404T160000 SEQUENCE:0 TRANSP:OPAQUE END:VEVENT END:VCALENDAR